Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALACE: Lanreotide Autogel in Chinese GEP-NETs
NCT04852679Phase 3Completed
- Sponsor
- Ipsen
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lanreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Ipsen. Started May 2021; status: completed.
02
Drugs
lanreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04852679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04852679.